financetom
Business
financetom
/
Business
/
What's Going On With Chegg Stock Tuesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Chegg Stock Tuesday?
Jun 18, 2024 6:34 AM

Chegg Inc ( CHGG ) shares are trading higher Tuesday after the company announced a restructuring plan as it refocuses its strategy around its core audience.

What Happened: After the market close on Monday, Chegg ( CHGG ) announced a restructuring plan including a 23% headcount reduction, a new brand and marketing strategy and a dedication of more resources to its international program.

Chegg ( CHGG ) said it will refocus on students with a comprehensive course load who are seeking positive learning outcomes. The company plans to diversify its distribution channels and execute on its strategy by reaching students in high school and earlier in college.

“Today, we executed a restructuring effort, a major step in my plans to refocus Chegg ( CHGG ) and return to subscriber and revenue growth,” said Nathan Schultz, president and CEO of Chegg ( CHGG ).

“These changes are designed to make us a more focused, more efficient, uncomplicated, and quicker-moving company. Our renewed focus on our core audience – the student – will allow us to address an unmet need with an offering that is differentiated, holistic, and verticalized for education.”

Chegg ( CHGG ) expects the restructuring to save the company between $40 million and $50 million in 2025. The company said it remains committed to achieving adjusted EBITDA margin of 30% or greater in 2025 and believes it can deliver at least $100 million in free cash flow next year. Chegg ( CHGG ) also reiterated its second-quarter guidance from April.

Don’t Miss: Why Rocket Lab Shares Are Gaining Today

CHGG Price Action: Chegg ( CHGG ) shares were up 18.7% at $3.09 at the time of publication, according to Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BridgeBio Says Study of Muscular Dystrophy Treatment Showed Motor, Pulmonary Improvements
BridgeBio Says Study of Muscular Dystrophy Treatment Showed Motor, Pulmonary Improvements
Oct 27, 2025
08:03 AM EDT, 10/27/2025 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Monday its phase 3 study of investigational oral therapy BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 showed clinically meaningful improvements in motor and pulmonary function. The study achieved all primary and secondary interim analysis endpoints with a well-tolerated safety profile, BridgeBio said. The primary interim...
Mazda forms EU carbon emissions pool with Changan joint venture
Mazda forms EU carbon emissions pool with Changan joint venture
Oct 27, 2025
MILAN (Reuters) -Japanese automaker Mazda ( MZDAF ) has teamed up with its joint venture with China's Changan to pool carbon credits and help avoid carbon emissions fines, an EU document showed. Several legacy carmakers face potential European Union fines as their shift to electric vehicles (EVs) has been slower than expected. But those with lower shares of EV sales...
Solve Industrial Motion Group acquires Miller Bearing Company
Solve Industrial Motion Group acquires Miller Bearing Company
Oct 27, 2025
Solve Industrial Motion Group has acquired Miller Bearing Company, a domestic manufacturer of conveyor bearings. CHARLOTTE, N.C., Oct. 27, 2025 /PRNewswire/ -- Solve Industrial Motion Group (Solve), a leading provider of engineered bearings and power transmission solutions, has today announced its acquisition of Miller Bearing Company (Miller) a US manufacturer located in Kent, Ohio, specializing in conveyor bearings. The Miller...
Zenas BioPharma Says Phase 2 Obexelimab Trial Meets Endpoint in Relapsing Multiple Sclerosis
Zenas BioPharma Says Phase 2 Obexelimab Trial Meets Endpoint in Relapsing Multiple Sclerosis
Oct 27, 2025
08:10 AM EDT, 10/27/2025 (MT Newswires) -- Zenas BioPharma ( ZBIO ) said Monday that a phase 2 trial of obexelimab in relapsing multiple sclerosis achieved its primary endpoint, with a 95% reduction in new gadolinium-enhancing T1 hyperintense lesions compared with placebo. The near-complete suppression of gadolinium-enhancing T1 hyperintense lesions, which are markers of active inflammation, was observed by week...
Copyright 2023-2026 - www.financetom.com All Rights Reserved